29^th European Nephrology Conference

Immunomodulation and Targeted Therapies for Glomerular Diseases

Immunomodulation and targeted therapies are at the forefront of advancing treatment for glomerular diseases, such as focal segmental glomerulosclerosis (FSGS) and minimal change disease. These approaches aim to precisely address the underlying immune dysfunction and pathology associated with glomerular disorders. Immunomodulation involves the use of agents that can modify or suppress inappropriate immune responses, thereby reducing inflammation and preventing further kidney damage. Targeted therapies, on the other hand, focus on specific molecular pathways and cell types involved in disease progression. For example, novel biologics and small molecules can selectively inhibit harmful immune cells or cytokines involved in glomerular injury. Combining these strategies with personalized medicine allows for more effective and individualized treatment plans, minimizing side effects and improving patient outcomes. Recent advancements in these therapies offer hope for better management of glomerular diseases, potentially leading to improved kidney function and quality of life for affected individuals.